Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Veritas In Silico Inc. ( (JP:130A) ).
Veritas In Silico Inc. has ended its collaborative research with Takeda Pharmaceutical on mRNA-targeted small-molecule drugs, a partnership that began in June 2023 and had produced some initial results. The termination, effective April 13, 2026, was reached amicably, and both parties plan to continue discussions on how to apply the research findings in future initiatives.
The company stated that the end of this collaboration is expected to have only a limited impact on its business performance and will not alter its earnings forecast for the fiscal year ending December 2026. Veritas In Silico indicated it will disclose any material developments that arise, signaling that it aims to manage investor expectations while maintaining flexibility for future alliances or projects based on the terminated research.
More about Veritas In Silico Inc.
Veritas In Silico Inc. is a biotechnology company listed on the Tokyo Stock Exchange Growth market that focuses on discovering and developing mRNA-targeted small-molecule drugs. The company pursues collaborative research with major pharmaceutical partners to advance novel modalities in drug discovery and build a pipeline around RNA-based therapeutic approaches.
Average Trading Volume: 145,948
Technical Sentiment Signal: Hold
Current Market Cap: Yen3.17B
For a thorough assessment of 130A stock, go to TipRanks’ Stock Analysis page.